Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) – Pipeline Review, H2 2017

Global Markets Direct’s, ‘Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) – Pipeline Review, H2 2017’, provides in depth analysis on Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) targeted pipeline therapeutics. The report provides comprehensive information complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) targeted therapeutics development and features dormant and discontinued projects. The report analyses the pipeline products from therapy areas Immunology, Oncology and Cardiovascular under development targeting Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA).

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

*Updated report will be delivered in 48 hours of order confirmation.

Scope

The report provides a snapshot of the global therapeutic landscape for Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA)

The report reviews Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) targeted therapeutics and enlists all their major and minor projects

The report assesses Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) targeted therapeutics

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

Alkermes Plc

Celgene Corp

Medicenna Therapeutics Corp

Nektar Therapeutics

Philogen SpA

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) - Overview

Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) - Companies Involved in Therapeutics Development

Alkermes Plc

Celgene Corp

Medicenna Therapeutics Corp

Nektar Therapeutics

Philogen SpA

Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) - Drug Profiles

ALKS-4230 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

APT-602 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

basiliximab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

basiliximab biobetter - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

daclizumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Darleukin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Daromun - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DEL-106 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MDNA-209 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NKTR-358 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) - Dormant Products

Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) - Product Development Milestones

Featured News & Press Releases

Oct 12, 2017: Philogen Announces Authorization from FDA of a Pivotal Registration Trial in USA for the Treatment of Resectable Melanoma

Jul 10, 2017: Nektar Presents New Preclinical Data for NKTR-358, a First-in-Class Regulatory T Cell Stimulator, at 13th World Congress of Inflammation in London

Jul 07, 2017: EMA restricts use of multiple sclerosis medicine Zinbryta

Jun 09, 2017: EMA reviews multiple sclerosis medicine Zinbryta

May 03, 2017: Nektar Appoints Brian L. Kotzin, M.D. as Head of Clinical Development for Nektar's Immunology Program

Apr 10, 2017: Biogen's Zinbryta accepted for use in NHS Scotland

Mar 27, 2017: Alkermes to Present Preclinical Data on ALKS 4230 at the American Association for Cancer Research Annual Meeting

Mar 27, 2017: Nektar Therapeutics Initiates Clinical Study of NKTR-358, a First-in-Class Regulatory T Cell Stimulator, Being Developed for the Treatment of Immune and Inflammatory Disorders

Mar 15, 2017: Nice Recommends Biogen's Zinbryta (Daclizumab) For Relapsing-Remitting Multiple Sclerosis

Dec 09, 2016: Biogen and AbbVie Receive Health Canada Approval of Once-Monthly ZINBRYTA (Daclizumab Beta) for Multiple Sclerosis

Sep 15, 2016: New Data Presented at ECTRIMS Reinforce Efficacy of ZINBRYTA (Daclizumab) and Support Long-Term Safety Profile

Sep 08, 2016: Biogen Demonstrates Data on ZINBRYTA at the 32nd congress of the European Committee for Treatment and Research in Multiple Sclerosis

Aug 15, 2016: Diplomat to Dispense ZINBRYTA for the Treatment of Multiple Sclerosis

Jul 05, 2016: Biogen and AbbVie’s Once-Monthly ZINBRYTA (Daclizumab) Approved in European Union for Treatment of Multiple Sclerosis

May 27, 2016: Biogen and AbbVie Receive FDA Approval of Once-Monthly ZINBRYTA (daclizumab) for Multiple Sclerosi

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development by Stage of Development, H2 2017

Number of Products under Development by Therapy Areas, H2 2017

Number of Products under Development by Indication, H2 2017

Number of Products under Development by Companies, H2 2017

Products under Development by Companies, H2 2017

Number of Products by Stage and Mechanism of Actions, H2 2017

Number of Products by Stage and Route of Administration, H2 2017

Number of Products by Stage and Molecule Type, H2 2017

Pipeline by Alkermes Plc, H2 2017

Pipeline by Celgene Corp, H2 2017

Pipeline by Medicenna Therapeutics Corp, H2 2017

Pipeline by Nektar Therapeutics, H2 2017

Pipeline by Philogen SpA, H2 2017

Dormant Products, H2 2017

Dormant Products, H2 2017 (Contd..1), H2 2017

List of Figures

List of Figures

Number of Products under Development by Stage of Development, H2 2017

Number of Products under Development by Therapy Areas, H2 2017

Number of Products under Development by Top 10 Indications, H2 2017

Number of Products by Mechanism of Actions, H2 2017

Number of Products by Stage and Mechanism of Actions, H2 2017

Number of Products by Routes of Administration, H2 2017

Number of Products by Stage and Routes of Administration, H2 2017

Number of Products by Molecule Types, H2 2017

Number of Products by Stage and Molecule Types, H2 2017

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports